PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34932238-1	2022	BACKGROUND: Ozanimod, a high selective sphingosine 1 phosphate (S1P) receptor (S1PR) 1/5 modulator was approved by the Food and Drug Administration for the treatment of adult patients with moderately to severely active ulcerative colitis.	ozanimod	12-20	sphingosine-1-phosphate receptor 1	Homo sapiens	79-88	
34007159-3	2021	Ozanimod is an oral drug belonging to the sphingosine-1-phosphate receptor (S1PR) modulator family recently approved in different countries for MS with active disease.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	76-80	
34007159-8	2021	This article retraces the itinerary leading to the approval of ozanimod for MS treatment and its peculiarities and potentiality inside the S1PR modulator family.	ozanimod	63-71	sphingosine-1-phosphate receptor 1	Homo sapiens	139-143	
32570252-11	2020	Ozanimod, an S1PR1 and S1PR5 inhibitor, has been successfully tested in initial studies in UC.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	13-18	
31317509-11	2019	Similarly, ozanimod, an S1P1 and S1P5 receptor agonist, has shown early favorable results and is enrolling in phase III trials.	ozanimod	11-19	sphingosine-1-phosphate receptor 1	Homo sapiens	24-46	
33658933-2	2020	As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P3 receptor activation.	ozanimod	73-81	sphingosine-1-phosphate receptor 1	Homo sapiens	103-107	
32810927-2	2020	The latter is exploited in the approval and/or late-stage development of receptor-desensitizing agents targeting the S1P1 receptor in multiple sclerosis, such as siponimod, ozanimod and ponesimod.	ozanimod	173-181	sphingosine-1-phosphate receptor 1	Homo sapiens	117-121	
26990079-0	2016	Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	31-65	
26990079-0	2016	Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.	ozanimod	0-8	sphingosine-1-phosphate receptor 1	Homo sapiens	67-71